R&D, Real estate

Allergan joins the great biopharma R&D migration to Cambridge

Dublin-based Allergan $AGN is opening up an R&D shop in Cambridge, MA, looking for a clear window into the kind of scientific innovation in the area that has made it into one of the world’s premier biotech hubs.

Don Frail

Don Frail, the senior vice president of research and external scientific innovation, is taking the lead on the new facility, which opens in Q1 of this year.

There’s no immediate word on just how many people will be involved, or how big it is, but Allergan is clearly interested in tapping into the local community for new ideas and deals.

David Nicholson, Allergan

“Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and start ups in the area,” said David Nicholson, the EVP and chief R&D officer at the company.

The biotech’s R&D HQ will remain in Irvine, CA, with R&D sites in Madison, NJ and San Francisco area.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->